Company / Cash & Equivalents
UroGen Pharma Ltd. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$110.7M
FY2025
5-year range
$44.4M / $172.0M
FY2021-FY2025
Trend
-35.6%
vs FY2024
Sector context
#136 of 207
Health Care
What the data says
At $111M, UroGen Pharma Ltd.'s cash & equivalents ranks #136 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 9 years, ranging from $37M in FY2017 to $172M in FY2024.
Based on SEC 10-K filings.
$111M in FY2025 with a 5-year CAGR of +15.9%.
Improved from $95M to $111M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +26.0%
- 5-Year CAGR
- +15.9%
- 10-Year CAGR
- -
Sector benchmark
#136 of 207 in Health CareTop 66% of 207This company $110.7M Sector average $669.5M
▼
-83.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.9%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 35.6% year-over-year.
- Ranks #136 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $110.7M | -35.6% |
| FY2024 | $172.0M | +81.0% |
| FY2023 | $95.0M | +71.5% |
| FY2022 | $55.4M | +24.9% |
| FY2021 | $44.4M | -16.1% |
| FY2020 | $52.9M | +6.4% |
| FY2019 | $49.7M | -51.0% |
| FY2018 | $101.3M | +173.8% |
| FY2017 | $37.0M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026